AstraZeneca is advancing its ambition to transform haematology care with new data from its expanding pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from 6–9 December 2025.

This year marks the company’s largest presence at ASH, featuring 65 abstracts across eight approved and investigational medicines, including 15 oral presentations. Key data include updated three-year results from the phase I trial of surovatamig, a CD19xCD3 T-cell engager, in relapsed or refractory follicular lymphoma; initial findings from the DURGA-1 phase Ib/II study assessing AZD0120, an investigational BCMAxCD19 CAR T therapy, in relapsed or refractory multiple myeloma; results from the ECHO phase III trial evaluating Calquence with bendamustine and rituximab in first-line mantle cell lymphoma; and new outcomes from the ALXN1210-TMA-314 phase III study assessing Ultomiris in paediatric patients with haematopoietic stem cell transplant-associated thrombotic microangiopathy.

AstraZeneca leaders highlighted the company’s progress in developing therapies with the potential to redefine care across B-cell malignancies, multiple myeloma, and rare haematologic conditions. New data for AZD0120, AstraZeneca’s first cell therapy, and for surovatamig demonstrate meaningful early efficacy and safety signals across several blood cancers. Additionally, Alexion will present new results showing clinically significant survival benefits and improved outcomes with Ultomiris in rare haematologic disorders, reinforcing its commitment to expanding the potential of complement biology.

Further presentations include updated data on surovatamig in B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma; new follow-up results from investigator-initiated trials in China evaluating AZD0120 in newly diagnosed high-risk multiple myeloma; early findings from the TrAVeRse phase II trial studying Calquence with venetoclax and rituximab in treatment-naïve mantle cell lymphoma; exploratory subgroup analyses from the AMPLIFY phase III trial in chronic lymphocytic leukaemia; and additional insights from the ALPHA phase III trial on Voydeya as an add-on therapy in paroxysmal nocturnal haemoglobinuria. Real-world evidence on Ultomiris across diverse patient groups, including pregnant patients, will also be shared.

AstraZeneca continues to push scientific boundaries to reshape haematology care through innovative medicines informed by the needs of patients, caregivers and clinicians. The company is building world-class cell therapy capabilities and advancing a robust pipeline enabled by CAR T, TCR T, and CAR Treg platforms, aiming to unlock the full curative potential of cell-based treatments. AstraZeneca’s broader vision is to revolutionise oncology by pursuing cures across cancer types, while Alexion remains committed to transforming outcomes for people living with rare and devastating diseases through cutting-edge science and a growing, diversified pipeline. The company continues to focus on developing and delivering life-changing therapies across oncology, rare diseases, and key biopharmaceutical areas.